GSK invests $50 million in US $250 million venture capital fund
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline is to invest $50 million in a $250 million venture capital fund, known as Sanderling VII, as it is managed by Sanderling Ventures, a San Mateo, California-based investment firm.